We employ a precise process to review grant applications, ensuring the most innovative projects with the greatest potential to reach patients quickly are selected. We will not fund a project that does not demonstrate commercial potential. Submitted proposals undergo a rigorous evaluation of scientific merit, clinical feasibility and commercialization potential through collaboration of our key advisory councils. Each proposal is reviewed by our Scientific Review Committee comprised of experts in academic pediatric oncology, and experts in pediatric oncology drug development via our Industry Advisory Council. The most promising proposals are further affirmed by our Scientific Advisory Council.
Dr. Alex Kentsis
Alex Kentsis is a pediatric oncologist and cancer biologist. His research takes advantage of modern technologies to improve our understanding of the biologic causes of blood and solid tumors. Together with colleagues, he has made discoveries about new therapeutic targets in cancer cells, mechanisms by which cancer cells can evade new treatments, and improved strategies to overcome treatment resistance. Recently, his lab has identified new mechanisms of aberrant gene control and resistance to apoptosis in acute myeloid leukemias, and mechanisms of site-specific oncogenic mutations and DNA repair dependencies in solid tumors. These studies define precise molecular mechanisms that would lead to rational therapeutic strategies for patients.
Dr. Stephen Sallan received his MD from Wayne State University School of Medicine in 1967. He completed residencies in pediatrics at the Boston Floating Hospital (1968), Children’s Hospital of Philadelphia (1969), and the Hospital for Sick Children, London (1970). In 1973, he served as a fellow in pediatric oncology at Boston Children’s Hospital and DFCI, where he joined the staff in 1975. He was named chief of staff and chairman of the Medical Staff Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan’s clinical research focuses on the genetic heterogeneity of ALL, understanding the reasons for disease recurrence and drug resistance, developing new, more specific therapies, and conducting all such research in the context of diminishing the toxicity of treatment. Current endeavors expand investigations to adults with ALL and also extend the laboratory discoveries to other malignancies including lymphoma and adult cancer. Dr. Sallan has served as the Chair of the CureSearch Scientific Review Committee since 2014.